Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Obalon Therapeutics Inc    OBLN

OBALON THERAPEUTICS INC (OBLN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Glancy Prongay & Murray LLP : Files Securities Class Action Lawsuit Against Obalon Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/15/2018 | 12:40am CET

Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of a class (the “Class”) consisting of persons and entities that acquired Obalon Therapeutics, Inc., (“Obalon” or the “Company”) (NASDAQ: OBLN) securities between October 5, 2016 and January 23, 2018, inclusive (the “Class Period”).

If you are a member of the Class described above, you may move the Court no later than 60 days from the date of this notice, to serve as lead plaintiff. Please contact Lesley Portnoy at 888-773-9224 or 310-201-9150, or at [email protected] to discuss this matter.

On January 23, 2018, Obalon issued a press release disclosing that “a purported whistleblower contacted KPMG LLP, the Company’s independent auditors, to make certain allegations relating to allegedly improper revenue recognition during the Company’s fourth fiscal quarter of 2017.” The Company further stated that “Obalon’s Audit Committee will oversee an internal investigation of these allegations.”

On this news, Obalon’s stock price fell $1.73 per share, or 33.3%, to close at $3.46 per share on January 23, 2018, on unusually heavy volume. The $3.46 closing price represented a total decline of $11.54, or nearly 77%, from the IPO price of $15.00 per share.

The filed complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that the Company recognized revenue in violation of Generally Accepted Accounting principles (“GAAP”); (2) that the Company lacked adequate internal controls over accounting and financial reporting; and (3) that, as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Obalon’s business, operations, and prospects, were materially false and misleading at all relevant times.

If you purchased shares of Obalon during the Class Period you may move the Court no later than 60 days from the date of this notice to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to [email protected], or visit our website at www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on OBALON THERAPEUTICS INC
12:26aOBALON Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedin..
BU
02/21OBALON THERAPEUTICS INC : Pawar Law Group Announces a Securities Class Action La..
AC
02/21OBALON THERAPEUTICS : Obalons Audit Committee Investigation of Whistleblower All..
AQ
02/20SHAREHOLDER INVESTIGATION NOTICE : The Schall Law Firm Announces it is Investiga..
AQ
02/20SCOTT+SCOTT, ATTORNEYS AT LAW, LLP : Alerts Investors to the Filing of Securitie..
BU
02/20Obalon’s Audit Committee Investigation of Whistleblower Allegation Find..
GL
02/19ROBBINS ARROYO LLP : Obalon Therapeutics, Inc. (OBLN) Misled Shareholders Accord..
BU
02/15Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Ob..
BU
02/15OBALON THERAPEUTICS INC : ONGOING The Schall Law Firm Announces it is Investigat..
AC
02/15OBALON Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedin..
BU
More news
News from SeekingAlpha
02/21YOUR DAILY PHARMA SCOOP : Portola Update, Wave Life Sciences To Collaborate With.. 
02/20Obalon "all clear" after completing inquiry into possible improper FQ4 revenu.. 
01/25YOUR DAILY PHARMA SCOOP : Portola Still Attractive, Johnson & Johnson Reports Q4.. 
01/23Obalon shares halted pending news 
01/23Obalon Therapeutics cancels stock offering on alleged improper Q4 revenue rec.. 
Financials ($)
Sales 2017 10,1 M
EBIT 2017 -32,1 M
Net income 2017 -32,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 9,49x
Capi. / Sales 2018 4,40x
Capitalization 95,9 M
Chart OBALON THERAPEUTICS INC
Duration : Period :
Obalon Therapeutics Inc Technical Analysis Chart | OBLN | US67424L1008 | 4-Traders
Technical analysis trends OBALON THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 12,0 $
Spread / Average Target 186%
EPS Revisions
Managers
NameTitle
Andrew P. Rasdal President, Chief Executive Officer & Director
Kim P. Kamdar Chairman
Kelly Huang Chief Operating Officer
William John Plovanic Chief Financial Officer & Secretary
Mark Brister Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
OBALON THERAPEUTICS INC-36.01%96
STRYKER CORPORATION2.52%59 148
SMITH & NEPHEW-1.24%15 580
JAPAN LIFELINE CO., LTD.45.67%2 897
WRIGHT MEDICAL GROUP NV-9.19%2 109
GLAUKOS CORP21.75%1 081